{"id":"chf-5188-pmdi","_chembl":null,"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T03:26:18.484Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123793,"model":"claude-sonnet-4-5-20250929"},"description":"CHF 5188 pMDI is an investigational pressurized metered-dose inhaler (pMDI) formulation being developed by Chiesi Farmaceutici for respiratory conditions. The compound is currently in Phase 2 clinical development, though specific molecular targets and therapeutic indications have not been publicly disclosed.","indications":{"approved":[{"status":"investigational","condition":"Respiratory disease (specific indication not disclosed)","patientPopulation":"Not disclosed"}]},"trialDetails":[{"nctId":"NCT01070524","phase":"PHASE2","title":"Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-01","conditions":"Asthma","enrollment":113}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CHF 5188 pMDI","genericName":"CHF 5188 pMDI","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}